• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Halaven (Breast Cancer) - Analysis and Forecasts to 2020 Product Image

Halaven (Breast Cancer) - Analysis and Forecasts to 2020

  • ID: 2114429
  • December 2011
  • 46 pages
  • GlobalData

Halaven (Breast Cancer) – Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Halaven (Breast cancer) - Analysis and Forecasts to 2020” provides Halaven sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Halaven including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the READ MORE >

Note: Product cover images may vary from those shown

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Breast Cancer Market
2.2 Epidemiology
2.3 Etiology and Risk Factors
2.3.1 Age and Gender
2.3.2 Genetic Inheritance
2.3.3 Hormone Replacement Therapy
2.3.4 Radiation
2.3.5 Obesity
2.3.6 Alcohol Consumption
2.3.7 Late Child Birth
2.3.8 Use of Birth Control Pills
2.4 GlobalData Report Guidance
3 Breast Cancer: Market Characterization
3.1 Breast Cancer Market
3.2 Breast Cancer Market Forecasts and CAGR
3.3 Drivers of Breast Cancer Market
3.3.1 Breast Cancer: Most Frequent Cancer in Women
3.3.2 Increasing Breast Cancer Incidence Rate
3.3.3 Decreasing Breast Cancer Mortality Rate
3.3.4 High Survival Rates of Breast Cancer
4 Staging of Breast Cancer: Introduction
4.1 Distribution of Patients by Stages
4.1.1 Stages
5 Predictive Biomarker in the Treatment of Breast Cancer
6 Treatment Options of Breast Cancer
6.1 Stage 0 Breast Cancer: Treatment Options
6.2 Early Stage Breast Cancer (Excluding Stage 0)
6.3 Metastatic Breast Cancer (MBC)
6.3.1 Endocrine treatment: Adjuvant, First Line and Second Line
6.3.2 Cytotoxic Chemotherapy
6.3.3 Management of Patients with HER-2 Positive Patients
7 Halaven
7.1 Introduction
7.2 Mechanism of Action
7.3 Clinical Studies
7.4 Approval History of Halaven
7.5 Factors Affecting Sales of Halaven
7.5.1 Low Efficacy
7.5.2 Increasing Competition from Targeted Therapy
7.5.3 NICE Rejection
7.6 Drug Evaluation
7.6.1 Drug Risk Benefit Score
7.6.2 Intensity of Competition
7.7 Sales Forecasts
7.7.1 Target Patient Pool of Halaven
7.7.2 Dosing
7.7.3 Market Penetration
7.7.4 Annual Cost of Therapy
7.7.5 Sales Projections of Halaven
8 Breast Cancer Market: Appendix
8.1 Market Definitions
8.2 List of Abberiviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Number of Patients Approved to take the Drug
8.3.5 Net Penetration of Drug
8.3.6 Net Annual Dosing
8.3.7 Annual Cost of Therapy
8.4 Drug Sales Estimates Model
8.5 Contact Us
8.6 Disclaimer
8.7 Sources

1.1 List of Tables
Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030
Table 2: Five-Year Relative Survival Rates, 2005, By Stages
Table 3: Summary of Best Objective Tumor Response in Phase 2 Study
Table 4: Approval History of Halaven
Table 5: Drug Risk Benefit Score, Halaven
Table 6: Annual Cost of Therapy, Halaven, 2011
Table 7: Halaven, Breast Cancer, Global,Sales Forecasts ($m), 2010–2020
Table 8: Halaven, Breast Cancer, The US, Sales Forecasts ($m), 2010–2020
Table 9: Halaven, Breast Cancer, The UK, Sales Forecasts ($m), 2011–2020
Table 10: Halaven, Breast Cancer, France, Sales Forecasts ($m), 2012–2020
Table 11: Halaven, Breast Cancer, Germany, Sales Forecasts ($m), 2011–2020
Table 12: Halaven, Breast Cancer, Italy, Sales Forecasts ($m), 2012–2020
Table 13: Halaven, Breast Cancer, Spain, Sales Forecasts ($m), 2011–2020
Table 14: Halaven, Breast Cancer, Japan, Sales Forecasts ($m), 2011–2020

1.2 List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020
Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030
Figure 6: All Cancers, Incidence, Worldwide, 2008-2030
Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030
Figure 9: All Cancers, Mortality, Worldwide, 2008-2030
Figure 10: Broad Classification of Breast Cancer, By Type
Figure 11: Classification of Non-Invasive Breast Cancer, By CIS
Figure 12: Classification of Invasive Breast Cancer, By Stages
Figure 13: Classification of Invasive Breast Cancer, By Treatment
Figure 14: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer
Figure 15: Breast Cancer Intrinsic Sub Types used for deciding Treatment Options for MBC
Figure 16: Breast Cancer Types in Decreasing Order of their Aggressiveness
Figure 17: Treatment Options, DCIS Breast Cancer
Figure 18: Treatment Options, LCIS Breast Cancer
Figure 19: Treatment Options, Stages I, II and IIIA
Figure 20: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer)
Figure 21: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer)
Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer)
Figure 23: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer
Figure 24: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC
Figure 25: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer
Figure 26: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer
Figure 27: Drug Model Diagram of Halaven
Figure 28: Halaven, Breast Cancer, Global,Sales Forecasts ($m), 2010–2020
Figure 29: Halaven, Breast Cancer, The US, Sales Forecasts ($m), 2010–2020
Figure 30: Halaven, Breast Cancer, The UK, Sales Forecasts ($m), 2011–2020
Figure 31: Halaven, Breast Cancer, France, Sales Forecasts ($m), 2012–2020
Figure 32: Halaven, Breast Cancer, Germany, Sales Forecasts ($m), 2011–2020
Figure 33: Halaven, Breast Cancer, Italy, Sales Forecasts ($m), 2012–2020
Figure 34: Halaven, Breast Cancer, Spain, Sales Forecasts ($m), 2011–2020
Figure 35: Halaven, Breast Cancer, Japan, Sales Forecasts ($m), 2011–2020
Figure 36: Halaven, Breast Cancer, Global, Sales Distribution (%), 2018
Figure 37: Patients Approved for the Drug

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos